Edwards has invested $35 million in an exclusive right to acquire Corvia Medical Inc., the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction. The company's InterAtrial Shunt Device is designed to provide continuous and dynamic decompression of the left atrium, which may reduce symptoms and slow the progression of heart failure. The therapy has received CE mark in Europe and is being studied as part of a Food and Drug Administration pivotal clinical trial.
Separately, Edwards has also acquired certain assets of Mitralign Inc., including intellectual property and associated clinical and regulatory experience. Mitralign is a developer of an investigational transcatheter annuloplasty system designed to treat functional mitral and tricuspid regurgitation.
Additional terms of these transactions remain confidential. This announcement is not expected to impact Edwards' 2019 financial guidance.